implications of using adjuvant sorafenib and sunitinib in unfavourable renal carcinoma
Published 9 years ago • 173 plays • Length 8:11Download video MP4
Download video MP3
Similar videos
-
4:03
adjuvant treatment with sorafenib or sunitinib doesn't improve outcomes in localised renal carcinoma
-
2:11
dr. haas on adjuvant sorafenib or sunitinib for rcc
-
3:49
adjuvant sunitinib for renal cell carcinoma
-
2:07
haas: sorafenib/sunitinib for unfavorable rcc
-
2:23
s-trac phase iii trial of sunitinib as adjuvant therapy in high-risk renal cell cancer patients
-
1:03
dr. barocas on adjuvant sunitinib in renal cell carcinoma
-
0:55
selecting patients with renal cell carcinoma for adjuvant sunitinib therapy
-
19:55
adjuvant sunitinib for high risk renal cell carcinoma: not ready for prime time
-
3:00
adjuvant sunitinib in renal cell carcinoma
-
6:03
tackling renal cancer with a combination of autologous immunotherapy and sunitinib
-
9:30
study on avelumab and axitinib vs sunitinib in the treatment of advanced renal cell carcinoma
-
4:39
avelumab and axitinib vs sunitinib in treating advanced renal cell carcinoma
-
3:57
agile trial: frontline axitinib versus sorafenib in metastatic renal cell carcinoma
-
0:50
dr. viktor grünwald on dovitinib versus sorafenib in metastatic renal cell carcinoma
-
1:05
dr. balar on phase iii assure trial results for rcc
-
59:55
renal cell carcinoma: past, present, and future
-
3:01
a phase iii trial of pembrolizumab as adjuvant treatment for renal cell carcinoma
-
7:16
adjuvant therapy in high-risk renal cell cancer
-
26:50
management of toxicities related to systemic therapy for metastatic renal cell carcinoma